Science News
from research organizations

Fenofibrate may reduce heart disease risk in some patients with type 2 diabetes

Date:
December 28, 2016
Source:
NIH/National Heart, Lung and Blood Institute
Summary:
A new study shows that the drug fenofibrate might reduce the risk of cardiovascular events in patients with type 2 diabetes who have high levels of triglycerides and low levels of 'good' cholesterol, despite being treated with statins.
Share:
FULL STORY

A new study shows that the drug fenofibrate might reduce the risk of cardiovascular events in patients with type 2 diabetes who have high levels of triglycerides and low levels of "good" cholesterol, despite being treated with statins. The study, funded by the National Heart, Lung, and Blood Institute (NHLBI), appears in the December 28 issue of JAMA Cardiology.

Fenofibrate is primarily used to help reduce elevated levels of triglycerides, or fat, in the blood. But the researchers wanted to know if the drug, when combined with statin treatment, could also reduce the risk of heart disease in people with type 2 diabetes. People with type 2 diabetes are at high risk of cardiovascular-related events, such as heart attacks, stroke, and even death, often because their levels of triglycerides are so high, and their high-density lipoprotein (HDL) cholesterol levels are low.

To answer their question, the researchers followed 4,640 participants from the NHLBI-funded Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Study for five years after the conclusion of the trial in 2009. The findings suggest that fenofibrate therapy may be beneficial in the way the researchers hoped: by reducing cardiovascular events in patients with type 2 diabetes who take statins but still have especially high triglycerides levels and low HDL cholesterol levels. However, a randomized study is needed to confirm these findings, according to the authors.


Story Source:

Materials provided by NIH/National Heart, Lung and Blood Institute. Note: Content may be edited for style and length.


Journal Reference:

  1. Marshall B. Elam, Henry N. Ginsberg, Laura C. Lovato, Marshall Corson, Joseph Largay, Lawrence A. Leiter, Carlos Lopez, Patrick J. O’Connor, Mary Ellen Sweeney, Daniel Weiss, William T. Friedewald, John B. Buse, Hertzel C. Gerstein, Jeffrey Probstfield, Richard Grimm, Faramarz Ismail-Beigi, David C. Goff, Jerome L. Fleg, Yves Rosenberg, Robert P. Byington. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. JAMA Cardiology, 2016; DOI: 10.1001/jamacardio.2016.4828

Cite This Page:

NIH/National Heart, Lung and Blood Institute. "Fenofibrate may reduce heart disease risk in some patients with type 2 diabetes." ScienceDaily. ScienceDaily, 28 December 2016. <www.sciencedaily.com/releases/2016/12/161228155958.htm>.
NIH/National Heart, Lung and Blood Institute. (2016, December 28). Fenofibrate may reduce heart disease risk in some patients with type 2 diabetes. ScienceDaily. Retrieved May 23, 2017 from www.sciencedaily.com/releases/2016/12/161228155958.htm
NIH/National Heart, Lung and Blood Institute. "Fenofibrate may reduce heart disease risk in some patients with type 2 diabetes." ScienceDaily. www.sciencedaily.com/releases/2016/12/161228155958.htm (accessed May 23, 2017).

RELATED STORIES